Skip to main content

Advertisement

SpringerLink
Log in

Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach

  • Methodology Research
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the shared mechanisms of scutellarin in angina pectoris (AP) and ischemic stroke (IS) treatment.

Methods

A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction, protein-protein interaction (PPI) data collection, network construction, network analysis, and enrichment analysis. Furthermore, molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.

Results

Two networks were established, including a disease-target network and a PPI network of scutellarin targets against AP and IS. Network analysis showed that 14 targets, namely, AKT1, VEGFA, JUN, ALB, MTOR, ESR1, MAPK8, HSP90AA1, NOS3, SERPINE1, FGA, F2, FOXO3, and STAT1, might be the therapeutic targets of scutellarin in AP and IS. Among them, NOS3 and F2 were recognized as the core targets. Additionally, molecular docking simulation confifirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2. Furthermore, enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways, such as coagulation cascades, mitogen-activated protein kinase (MAPK) signaling pathway, phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway, Toll-like receptor signaling pathway, hypoxia inducible factor-1 (HIF-1) signaling pathway, forkhead box O (FoxO) signaling pathway, tumor necrosis factor (TNF) signaling pathway, adipocytokine signaling pathway, insulin signaling pathway, insulin resistance, and estrogen signaling pathway.

Conclusions

The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant, anticoagulant, anti-inflammatory, and antioxidative effects as well as its effect on improving lipid metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56–e66.

    Article  PubMed  Google Scholar 

  2. Tan D, Wu JR, Cui YY, et al. Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for angina pectoris: a meta-analysis of 41 randomized controlled trials. Chin J Integr Med 2018;24:930–937.

    Article  CAS  PubMed  Google Scholar 

  3. Tan D, Wu JR, Zhang XM, et al. Sodium tanshinone II A sulfonate injection as adjuvant treatment for unstable angina pectoris: a metaanalysis of 17 randomized con-trolled trials. Chin J Integr Med 2018;24:156–160.

    Article  CAS  PubMed  Google Scholar 

  4. Valdes-Marquez E, Parish S, Clarke R, et al. Relative effects of LDL-C on ischemic stroke and coronary disease: a Mendelian randomization study. Neurology 2019;92:e1176–e1187.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Gaire BP. Herbal medicine in ischemic stroke: challenges and prospective. Chin J Integr Med 2018;24:243–246.

    Article  PubMed  Google Scholar 

  6. Li XM, Wang XY, Feng XW, et al. Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients. Brain Behav 2019:e01369.

    Google Scholar 

  7. Sun T, Wang X, Xu H. Ginkgo Biloba extract for angina pectoris: a systematic review. Chin J Integr Med 2015;21:542–550.

    Article  PubMed  Google Scholar 

  8. Huang Y, Wang L, Mao Y, et al. Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5. Front Neurol 2019;10:32.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Morishita T, Uzui H, Nakano A, et al. Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris. Heart Vessels 2018;33:1301–1310.

    Article  PubMed  Google Scholar 

  10. Hoffmann J, Haastert B, Brune M, et al. How do patients with diabetes report their comorbidities? Comparison with administrative data. Clin Epidemiol 2018;10:499–509.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Girot M, Deplanque D, Pasquier F, et al. Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease. J Neurol 2004;251:529–536.

    Article  PubMed  Google Scholar 

  12. Mo J, Yang R, Li F, et al. Scutellarin protects against vascular endothelial dysfunction and prevents atherosclerosis via antioxidation. Phytomedicine 2018;42:66–74.

    Article  CAS  PubMed  Google Scholar 

  13. Guo LL, Guan ZZ, Huang Y, et al. The neurotoxicity of beta-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin. Exp Toxicol Pathol 2013;65:579–584.

    Article  CAS  PubMed  Google Scholar 

  14. Shi ZH, Li NG, Wang ZJ, et al. Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo. Eur J Med Chem 2015;106:95–105.

    Article  CAS  PubMed  Google Scholar 

  15. Li Q, Wu JH, Guo DJ, et al. Suppression of diet-induced hypercholesterolemia by scutellarin in rats. Planta Med 2009;75:1203–1208.

    Article  CAS  PubMed  Google Scholar 

  16. Wang W, Ma X, Han J, et al. Neuroprotective effect of scutellarin on ischemic cerebral injury by down-regulating the expression of angiotensin-converting enzyme and AT1 receptor. PLoS One 2016;11:e0146197.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gao J, Chen G, He H, et al. Therapeutic effects of breviscapine in cardiovascular diseases: a review. Front Pharmacol 2017;8:289.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Lin LL, Liu AJ, Liu JG, et al. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 2007;50:327–332.

    Article  CAS  PubMed  Google Scholar 

  19. Muhammad J, Khan A, Ali A, et al. Network pharmacology: exploring the resources and methodologies. Curr Top Med Chem 2018;18:949–964.

    Article  CAS  PubMed  Google Scholar 

  20. Liu X, Wu J, Zhang D, et al. Network pharmacology-based approach to investigate the mechanisms of Hedyotis diffusa Willd. in the treatment of gastric cancer. Evid Based Complement Alternat Med 2018;2018:7802639.

    PubMed  PubMed Central  Google Scholar 

  21. Luo TT, Lu Y, Yan SK, et al. Network pharmacology in re-search of Chinese medicine formula: methodology, applica-tion and prospective. Chin J Integr Med 2020;26:72–80.

    Article  CAS  PubMed  Google Scholar 

  22. Wang Y, Guo G, Yang BR, et al. Synergistic effects of Chuanxiong- Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels. Chin J Integr Med 2017;23:654–662.

    Article  CAS  PubMed  Google Scholar 

  23. Kim S, Thiessen PA, Bolton EE, et al. PubChem Substance and Compound databases. Nucleic Acids Res 2016;44:D1202–D1213.

    Article  CAS  PubMed  Google Scholar 

  24. Wang X, Shen Y, Wang S, et al. Pharm Mapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 2017;45:W356–W360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. UniProt C. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019;47:D506–D515.

    Article  CAS  Google Scholar 

  26. Li YH, Yu CY, Li XX, et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res 2018;46:D1121–D1127.

    Article  CAS  PubMed  Google Scholar 

  27. Kohler S, Carmody L, Vasilevsky N, et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res 2019;47:D1018–D1027.

    Article  PubMed  CAS  Google Scholar 

  28. Pinero J, Bravo A, Queralt-Rosinach N, et al. DisGeNET: a comprehensive platform integrating information on human diseaseassociated genes and variants. Nucleic Acids Res 2017;45:D833–D839.

    Article  CAS  PubMed  Google Scholar 

  29. Liu X, Wu J, Zhang D, et al. A network pharmacology approach to uncover the multiple mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer. Evid Based Complement Alternat Med 2018;2018:6517034.

    PubMed  PubMed Central  Google Scholar 

  30. Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362–D368.

    Article  CAS  PubMed  Google Scholar 

  31. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498–2504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Liu H, Zeng L, Yang K, et al. A network pharmacology approach to explore the pharmacological mechanism of Xiaoyao Powder on anovulatory infertility. Evid Based Complement Alternat Med 2016;2016:2960372.

    PubMed  PubMed Central  Google Scholar 

  33. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003;4:2.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.

    Article  CAS  Google Scholar 

  35. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–2791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–461.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Lin H, Zhang W, Dong ZX, et al. A new and practical synthetic method for the synthesis of 6-O-methyl-scutellarein: one metabolite of scutellarin in vivo. Int J Mol Sci 2015;16:7587–7594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nassar BA, Bevin LD, Johnstone DE, et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J 2001;142:586–589.

    Article  CAS  PubMed  Google Scholar 

  40. Luizon MR, Pereira DA, Tanus-Santos JE. Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions. Pharmacogenomics 2018;19:1423–1435.

    Article  CAS  PubMed  Google Scholar 

  41. Johns R, Chen ZF, Young L, et al. Meta-analysis of NOS3 G894T polymorphisms with air pollution on the risk of ischemic heart disease worldwide. Toxics 2018;6:pii:E44.

    Article  CAS  Google Scholar 

  42. Rai H, Parveen F, Kumar S, et al. Association of endothelial nitric oxide synthase gene polymorphisms with coronary artery disease: an updated meta-analysis and systematic review. PLoS One 2014;9:e113363.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Yoshimura T, Hisatomi A, Kajihara S, et al. The relationship between insulin resistance and polymorphisms of the endothelial nitric oxide synthase gene in patients with coronary artery disease. J Atheroscler Thromb 2003;10:43–47.

    Article  CAS  PubMed  Google Scholar 

  44. Glueck CJ, Munjal J, Khan A, et al. Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal's angina pectoris. Am J Cardiol 2010;105:792–796.

    Article  CAS  PubMed  Google Scholar 

  45. Mao M, Sudhahar V, Ansenberger-Fricano K, et al. Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway. Free Radic Biol Med 2012;52:427–435.

    Article  CAS  PubMed  Google Scholar 

  46. Fan H, Ma X, Lin P, et al. Scutellarin prevents nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia via PI3K/AKTdependent activation of nuclear factor (erythroid-derived 2)- like 2 (Nrf2) in rats. Med Sci Monit 2017;23:5599–5612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Chinnaraj M, Planer W, Pozzi N. Structure of coagulation factor II: molecular mechanism of thrombin generation and development of next-generation anticoagulants. Front Med (Lausanne) 2018;5:281.

    Article  Google Scholar 

  48. Gong G, Qin Y, Huang W. Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo. Phytomedicine 2011;18:458–463.

    Article  CAS  PubMed  Google Scholar 

  49. Yildiz BS, Bilgin M, Zungur M, et al. Manual thrombus aspiration and the improved survival of patients with unstable angina pectoris treated with percutaneous coronary intervention (30 months follow-up). Medicine (Baltimore) 2016;95:e2919.

    Article  PubMed Central  Google Scholar 

  50. Kraft P, Schwarz T, Meijers JC, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One 2010;5:e11658.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Wilson SJ, Connolly TM, Peters G, et al. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis. Cardiovasc Res 2019;115:669–677.

    Article  CAS  PubMed  Google Scholar 

  52. Machida T, Dohgu S, Takata F, et al. Role of thrombin-PAR1- PKC theta/delta axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. Neuroscience 2017;350:146–157.

    Article  CAS  PubMed  Google Scholar 

  53. Zhang X, Guan J, Zhu H, et al. Simultaneous determination of scutellarin and tetrahydropalmatine of Deng-yan Granule in rat plasma by UFLC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2014;971:126–132.

    Article  CAS  PubMed  Google Scholar 

  54. Lu L, Qin Y, Chen C, et al. Beneficial effects exerted by paeonol in the management of atherosclerosis. Oxid Med Cell Longev 2018;2018:1098617.

    PubMed  PubMed Central  Google Scholar 

  55. Ozkaramanli Gur D, Guzel S, Akyuz A, et al. The role of novel cytokines in inflammation: defining peripheral artery disease among patients with coronary artery disease. Vasc Med 2018;23:428–436.

    Article  CAS  PubMed  Google Scholar 

  56. Cui X, Qian DW, Jiang S, et al. Scutellariae Radix and Coptidis Rhizoma improve glucose and lipid metabolism in T2DM rats via regulation of the metabolic profiling and MAPK/PI3K/Akt signaling pathway. Int J Mol Sci 2018;19:pii:E3634.

    Article  PubMed  CAS  Google Scholar 

  57. Fei X, Yuan W, Zhao Y, et al. Papain ameliorates the MPAs formation-mediated activation of monocytes by inhibiting Cox-2 expression via regulating the MAPKs and PI3K/Akt signal pathway. Biomed Res Int 2018;2018:3632084.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Gao W, Xiong Y, Li Q, et al. Inhibition of Toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to Nano therapeutics. Front Physiol 2017;8:508.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Polykratis A, van Loo G, Xanthoulea S, et al. Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis. Circulation 2012;126:1739–1751.

    Article  CAS  PubMed  Google Scholar 

  60. Yuan Y, Fang M, Wu CY, et al. Scutellarin as a potential therapeutic agent for microglia-mediated neuroinflammation in cerebral ischemia. Neuromolecular Med 2016;18:264–273.

    Article  CAS  PubMed  Google Scholar 

  61. Husain K, Hernandez W, Ansari RA, et al. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 2015;6:209–217.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Zhang Y, Zhong P, Xu Y, et al. Differential expression of TXNIP isoforms in the peripheral leukocytes of patients with acute myocardial infarction. Dis Markers 2018;2018:9051481.

    PubMed  PubMed Central  Google Scholar 

  63. Belaidi E, Morand J, Gras E, et al. Targeting the ROS-HIF-1- endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications. Pharmacol Ther 2016;168:1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Wang D, Wang L, Gu J, et al. Scutellarin inhibits high glucoseinduced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/ hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway. J Cardiovasc Pharmacol 2014;64:218–227.

    Article  CAS  PubMed  Google Scholar 

  65. Zhou P, Lu S, Luo Y, et al. Attenuation of TNF-alpha-induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-kappaB, JNK and p38 signaling pathways. Front Pharmacol 2017;8:464.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Gong J, Zhang L, Zhang Q, et al. Lentiviral vector-mediated SHC3 silencing exacerbates oxidative stress injury in nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with Parkinson's disease. Cell Physiol Biochem 2018;49:971–984.

    Article  CAS  PubMed  Google Scholar 

  67. Duan J, Liang S, Feng L, et al. Silica nanoparticles trigger hepatic lipid-metabolism disorder in vivo and in vitro. Int J Nanomed 2018;13:7303–7318.

    Article  CAS  Google Scholar 

  68. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 2006;368:1–19.

    Article  CAS  PubMed  Google Scholar 

  69. Pandeya PR, Lamichhane R, Lee KH, et al. Bioassay-guided isolation of active anti-adipogenic compound from royal jelly and the study of possible mechanisms. BMC Complement Altern Med 2019;19:33.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Ito S, Nagoshi T, Minai K, et al. Possible increase in insulin resistance and concealed glucose-coupled potassium-lowering mechanisms during acute coronary syndrome documented by covariance structure analysis. PLoS One 2017;12:e0176435.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Laakso M, Lehto S, Penttila I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with noninsulin- dependent diabetes. Circulation 1993;88:1421–1430.

    Article  CAS  PubMed  Google Scholar 

  72. Zhang Y, Ren P, Kang Q, et al. Effect of tetramethylpyrazine on atherosclerosis and SCAP/SREBP-1c signaling pathway in ApoE(- /-) mice fed with a high-fat diet. Evid Based Complement Alternat Med 2017;2017:3121989.

    PubMed  PubMed Central  Google Scholar 

  73. Sukocheva O, Wadham C, Gamble J, et al. Sphingosine-1- phosphate receptor 1 transmits estrogens' effects in endothelial cells. Steroids 2015;104:237–245.

    Article  CAS  PubMed  Google Scholar 

  74. Zhu JT, Choi RC, Chu GK, et al. Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem 2007;55:2438–2445.

    Article  CAS  PubMed  Google Scholar 

  75. Zhu JT, Choi RC, Li J, et al. Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease. Planta Med 2009;75:1489–1493.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Kunming Longjin Pharmaceutical Co., Ltd. for the information on breviscapine.

Author information

Authors and Affiliations

  1. Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China

    Zi-qi Meng, Jia-rui Wu, Ying-li Zhu, Wei Zhou, Xin-kui Liu, Shu-yu Liu, Meng-wei Ni & Si-yu Guo

  2. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China

    Chang-geng Fu

Authors
  1. Zi-qi Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia-rui Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying-li Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chang-geng Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xin-kui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shu-yu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Meng-wei Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Si-yu Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Meng ZQ and Wu JR conceived and designed the research; Zhou W, Liu SY, Ni MW and Guo SY collected and analyzed the data; Liu XK, Zhu YL and Fu CG provided useful suggestions on the methodology; and Meng ZQ wrote the paper. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Jia-rui Wu.

Ethics declarations

The authors declare no conflicts of interest in association with this manuscript.

Additional information

Supported by the National Natural Science Foundation of China (No. 81473547, No. 81673829) and Young Scientists Training Program of Beijing University of Chinese Medicine (No. BUCMYSTP-2019001); Cooperation Project of Beijing University of Chinese Medicine and Kunming Longjin Pharmaceutical (No. BUCM-YNLJ-2018001)

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meng, Zq., Wu, Jr., Zhu, Yl. et al. Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach. Chin. J. Integr. Med. 27, 62–69 (2021). https://doi.org/10.1007/s11655-020-2716-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-020-2716-4

Keywords

Search

Navigation